Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Rosalind Advisors Inc.’s 7th Largest Position

Rosalind Advisors Inc. trimmed its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 0.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,104,995 shares of the company’s stock after selling 15,175 shares during the period. Xeris Biopharma accounts for about 5.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 7th largest position. Rosalind Advisors Inc. owned about 2.09% of Xeris Biopharma worth $8,849,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Simplicity Wealth LLC acquired a new position in shares of Xeris Biopharma in the second quarter worth $27,000. Wealth Enhancement Advisory Services LLC purchased a new position in Xeris Biopharma in the 3rd quarter valued at about $35,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after purchasing an additional 15,929 shares during the last quarter. Bayesian Capital Management LP acquired a new position in shares of Xeris Biopharma in the first quarter valued at approximately $37,000. Finally, Asset Management Group Inc. lifted its stake in shares of Xeris Biopharma by 130.7% during the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after buying an additional 15,000 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Stock Performance

XERS opened at $3.26 on Wednesday. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.46 and a 1 year high of $3.39. The company’s 50 day simple moving average is $2.92 and its 200 day simple moving average is $2.46. The stock has a market capitalization of $485.74 million, a PE ratio of -7.58 and a beta of 2.70.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. The company had revenue of $48.07 million during the quarter, compared to analysts’ expectations of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same period in the previous year, the company earned ($0.14) EPS. As a group, sell-side analysts expect that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.